Health

Advisory

PNEUMOCOCCAL VACCINATION RECOMMENDED TO HELP PREVENT SECONDARY INFECTIONS

The Delaware Division of Public Health is forwarding this health alert from the Centers for Disease Control and Prevention. For more

information from the Division of Public Health, contact the immunization program at 1-800-282-8672.

Summary of Recommendations: CDC’s Advisory Committee on Immunization Practices (ACIP) recommends a single dose

of pneumococcal polysaccharide vaccine (PPSV) for all people 65 years of age and older and for persons 2 through 64 years of age with

certain high-risk conditions. Among those with high-risk conditions for pneumococcal disease, most are also at high risk for severe

complications from influenza. Special emphasis should be placed on vaccinating adults under 65 years of age who have established

high-risk conditions for pneumococcal disease; PPSV coverage among this group is low and this group may be more likely to develop

secondary bacterial pneumonia after an influenza infection. All children younger than 5 years of age should continue to receive

pneumococcal conjugate vaccine (PCV7) according to existing recommendations.

Situation:

Streptococcus pneumoniae (pneumococcus) remains a leading cause of vaccine-preventable illness and death in the United States.

Some of CDC’s Active Bacterial Core surveillance (ABCs) sites have seen greater than expected numbers of cases of invasive

pneumococcal disease coincident with increases in influenza-associated hospitalizations. A causal relationship between 2009 H1N1

influenza and this increase has not yet been established, but CDC is pursuing that question with state and local public health officials.

Influenza predisposes individuals to developing bacterial community-acquired pneumonia. During each of the influenza pandemics of the

20^th century, secondary bacterial pneumonia was a frequent cause of illness and death and S. pneumoniae was reported

as the most common etiology. These findings also apply to seasonal influenza. Recently, pneumococcal infections have been identified as

an important complication in severe and fatal cases of 2009 H1N1 influenza virus infection. A key difference between this

pandemic and those of the past is that now we have two pneumococcal vaccines that may help to prevent these infections.

Recommendations:

During the 2009-2010 influenza season, pneumococcal vaccines can be useful in preventing secondary pneumococcal infections and reducing

illness and death among those infected with influenza viruses.

CDC’s Advisory Committee on Immunization Practices (ACIP) recommends a single dose of pneumococcal polysaccharide vaccine (PPSV)

for all people 65 years of age and older and for persons 2 through 64 years of age with certain high-risk conditions. For those 19

through 64 years of age, these include: having asthma or smoking cigarettes. For those 2 through 64 years of age, high-risk conditions

include: chronic cardiovascular disease (congestive heart failure and cardiomyopathies), chronic pulmonary disease (including chronic

obstructive pulmonary disease and emphysema), diabetes mellitus, alcoholism, chronic liver disease (including cirrhosis), cerebrospinal

fluid leaks, cochlear implant, functional or anatomic asplenia including sickle cell disease and splenectomy, immunocompromising

conditions including HIV infection, leukemia, lymphoma, Hodgkin’s disease, multiple myeloma, generalized malignancy, chronic renal

failure, nephrotic syndrome; those receiving immunosuppressive chemotherapy (including corticosteroids); and those who have received an

organ or bone marrow transplant, and residents of nursing homes or long-term care facilities.

Among those with high-risk conditions for pneumococcal disease, most are also at high risk for severe complications from influenza.A

single pneumococcal revaccination at least five years after initial vaccination is recommended for people 65 years and older who were

first vaccinated before age 65 years. A single pneumococcal revaccination also is recommended for people at highest risk of disease, such

as those who have functional and anatomical asplenia, and those who have HIV infection, AIDS or malignancy and have at least five years

elapsed from receipt of first vaccination.

All people who have existing indications for PPSV should continue to be vaccinated according to current ACIP recommendations during the

2009 H1N1 influenza pandemic. Special emphasis should be placed on vaccinating adults under 65 years of age who have established

high-risk conditions for pneumococcal disease; PPSV coverage among this group is low and this group may be more likely to develop

secondary bacterial pneumonia after an influenza infection. PPSV is available for ordering through the usual process; ordering

PPSV is not linked to placing orders for monovalent 2009 H1N1 influenza vaccine.

Use of PPSV among people without current indications for vaccination is not recommended at this time.

All children younger than 5 years of age should continue to receive pneumococcal conjugate vaccine (PCV7) according to existing

recommendations.

According to existing guidelines, the use of a commercially available urine antigen test (Binax NOW®) is recommended for the

diagnosis of pneumococcal pneumonia in adults. Such testing, along with blood cultures and testing for influenza infection, can assist

clinicians in determining whether secondary pneumococcal pneumonia is occurring.

CDC recommends a yearly seasonal influenza vaccine as the first and most important step in protecting against seasonal influenza. Annual

influenza vaccination is especially important for people at high risk of serious influenza complications, including young children,

pregnant women, older adults, and people with certain chronic health conditions such as asthma, diabetes, heart or lung disease, and

neurologic conditions [including disorders of the brain, spinal cord, peripheral nerve, and muscle such as cerebral palsy, epilepsy

(seizure disorders), stroke, intellectual disability (mental retardation), moderate to severe developmental delay, muscular dystrophy, or

spinal cord injury]. Seasonal influenza vaccine also is important for health care workers and other people who live with or care for high

risk people to prevent giving the influenza to those at high risk.

A new monovalent vaccine against 2009 H1N1 influenza is available and is our best option for prevention of 2009 H1N1 infection. People at

greatest risk for 2009 H1N1 infection or serious complications and recommended to receive the first available doses of vaccine include

children, young adults age 19-24, pregnant women, and people age 25-64 with chronic health conditions. Monovalent 2009 H1N1 influenza

vaccine is important for close contacts of infants younger than 6 months of age and health care and emergency medical services personnel.

While vaccine supply is currently less than demand, additional doses are becoming available daily and supply will increase through

November and December.

In communities where 2009 H1N1 is circulating, treatment with influenza antiviral agents is recommended for all hospitalized patients

with confirmed, probable or suspected 2009 H1N1 or seasonal influenza and for outpatients who are at higher risk for influenza-related

complications. Empiric treatment of patients hospitalized with community acquired pneumonia should include both influenza antiviral

agents and appropriate antibiotic therapy. For more information on treatment of influenza, see http://www.cdc.gov/h1n1flu/recommendations.htm.

For More Information:

• For Clinicians: Prevention Of Pneumococcal Infections Secondary To Seasonal And 2009 H1N1 Influenza Viruses Infection (http://www.cdc.gov/h1n1flu/vaccination/provider/provider_pneumococcal.htm)
• Pneumococcal Vaccine Website (http://www.cdc.gov/vaccines/vpd-vac/pneumo/default.htm)
• Interim guidance for use of 23-valent pneumococcal polysaccharide vaccine during novel influenza A (H1N1) outbreak (http://www.cdc.gov/h1n1flu/guidance/ppsv_h1n1.htm)
• Nov 10 Letter to Providers Promoting PPSV for Adults (http://www.cdc.gov/h1n1flu/vaccination/provider/lettertoprovider.htm)
• CDC’s Morbidity and Mortality Weekly Report (MMWR):Letter to Providers Promoting PPSV for AdultsPolysaccharide Vaccine (Bacterial Coinfections in Lung Tissue Specimens from Fatal Cases

  of 2009 Pandemic Influenza A (H1N1) — United States, May–August 2009; September 29, 2009 / 58(Early Release);1-4 (http://www.cdc.gov/mmwr/PDF/wk/mm5838.pdf)

• Table: ACIP Recommendations for Use of Pneumococcal Polysaccharide Vaccine (http://www.cdc.gov/h1n1flu/vaccination/provider/provider_pneumococcal.htm#table1)
• Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-AcquiredPneumonia in Adults (http://www.journals.uchicago.edu/doi/pdf/10.1086/511159?)
• Preventing Seasonal Flu With Vaccination (http://www.cdc.gov/flu/protect/vaccine/index.htm)
• General Information About 2009 H1N1 Vaccines (http://www.cdc.gov/h1n1flu/vaccination/general.htm)
• Updated Interim Recommendations for the Use of Antiviral Medications in the Treatment and Prevention of Influenza for the 2009-2010Season (http://www.cdc.gov/h1n1flu/recommendations.htm)
• Interim Recommendations for Clinical Use of Influenza Diagnostic Tests During the 2009-10 Influenza Season (http://www.cdc.gov/h1n1flu/guidance/diagnostic_tests.htm)
• Active Bacterial Core surveillance (http://www.cdc.gov/abcs)

****

You are receiving this email because you are a registered member of the Delaware Health Alert Network.

If you are not a member and would like to subscribe, please complete the form found online at:  http://dhss.delaware.gov/main/mailforms/dph_hanform.aspx.

Please note: Some of the files available on this page are in Adobe PDF format which requires Adobe Acrobat Reader. A free copy of Adobe Acrobat Reader can be downloaded directly from Adobe . If you are using an assistive technology unable to read Adobe PDF, please either view the corresponding text only version (if available) or visit Adobe’s Accessibility Tools page.